| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer T Yokota, T Ura, N Shibata, D Takahari, K Shitara, M Nomura, C Kondo, ... British journal of cancer 104 (5), 856-862, 2011 | 458 | 2011 |
| Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non … Y Yamada, D Takahari, H Matsumoto, H Baba, M Nakamura, K Yoshida, ... The lancet oncology 14 (13), 1278-1286, 2013 | 275 | 2013 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 231 | 2019 |
| Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer J Matsubara, Y Yamada, Y Hirashima, D Takahari, NT Okita, K Kato, ... Clinical cancer research 14 (10), 3022-3029, 2008 | 176 | 2008 |
| Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma NT Okita, K Kato, D Takahari, Y Hirashima, TE Nakajima, J Matsubara, ... Gastric cancer 14, 161-165, 2011 | 154 | 2011 |
| A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with … S Ito, T Sano, J Mizusawa, D Takahari, H Katayama, H Katai, ... Gastric Cancer 20, 322-331, 2017 | 129 | 2017 |
| Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment K Shitara, Y Yatabe, K Matsuo, M Sugano, C Kondo, D Takahari, T Ura, ... Gastric cancer 16, 261-267, 2013 | 114 | 2013 |
| Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study C Kondoh, K Shitara, M Nomura, D Takahari, T Ura, H Tachibana, ... BMC palliative care 14, 1-6, 2015 | 101 | 2015 |
| Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy K Shitara, K Matsuo, I Oze, A Mizota, C Kondo, M Nomura, T Yokota, ... Cancer chemotherapy and pharmacology 68, 301-307, 2011 | 101 | 2011 |
| Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX K Shitara, K Matsuo, D Takahari, T Yokota, Y Inaba, H Yamaura, Y Sato, ... European journal of cancer 45 (10), 1757-1763, 2009 | 101 | 2009 |
| Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis Y Hirashima, Y Yamada, U Tateishi, K Kato, M Miyake, Y Horita, ... International journal of cancer 130 (10), 2359-2365, 2012 | 95 | 2012 |
| Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer T Wakatsuki, N Yamamoto, T Sano, K Chin, H Kawachi, D Takahari, ... Journal of gastroenterology 53, 1186-1195, 2018 | 78 | 2018 |
| Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer D Takahari, T Hamaguchi, K Yoshimura, H Katai, S Ito, N Fuse, ... Cancer chemotherapy and pharmacology 67, 1423-1428, 2011 | 72 | 2011 |
| Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel K Shitara, K Matsuo, D Takahari, T Yokota, T Shibata, T Ura, S Ito, ... Annals of oncology 21 (12), 2403-2409, 2010 | 71 | 2010 |
| Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation J Kato, M Kobune, S Ohkubo, K Fujikawa, M Tanaka, R Takimoto, ... Experimental hematology 35 (6), 879-887, 2007 | 66 | 2007 |
| Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912 D Takahari, N Boku, J Mizusawa, A Takashima, Y Yamada, T Yoshino, ... The oncologist 19 (4), 358-366, 2014 | 65 | 2014 |
| Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer T Yokota, S Hatooka, T Ura, T Abe, D Takahari, K Shitara, M Nomura, ... Anticancer research 31 (10), 3535-3541, 2011 | 65 | 2011 |
| Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer D Takahari, Y Yamada, NT Okita, T Honda, Y Hirashima, J Matsubara, ... Oncology 76 (1), 42-48, 2008 | 64 | 2008 |
| Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study K Shitara, K Matsuo, S Hatooka, T Ura, D Takahari, T Yokota, T Abe, ... Cancer science 101 (4), 1001-1006, 2010 | 63 | 2010 |
| Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy M Nomura, K Shitara, T Kodaira, S Hatooka, A Mizota, C Kondoh, ... International Journal of Radiation Oncology* Biology* Physics 82 (2), 946-952, 2012 | 61 | 2012 |
